Full year 2026 target total global revenue of approximately $875-$900M, including BRIUMVI U.S. net product revenue of approximately $825-$850M; Q1 2026 target BRIUMVI U.S. net product revenue of approximately $185-$190M. Full year 2026 target operating expense, defined as R&D and SG&A, of approximately $350 million excluding non-cash compensation, in addition to approximately $100 million in expenses associated with the subcutaneous BRIUMVI manufacturing costs and secondary manufacturer start-up costs. Announce pivotal topline data for ENHANCE trial combining Day 1 and Day 15 doses of IV BRIUMVI mid-year 2026; Present preliminary Phase 1 azer-cel data in Progressive MS in the second half of 2026; Announce pivotal topline data for subcutaneous BRIUMVI year-end 2026/1Q 2027; Commence registration-directed trial for BRIUMVI in an indication outside of MS; Commence additional exploratory studies for BRIUMVI and azer-cel in autoimmune disease.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics reports Q4 EPS 14c, consensus 33c
- TG Therapeutics expects cash to fund business based on current operating plan
- TGTX Upcoming Earnings Report: What to Expect?
- TG Therapeutics announces long-term data on Briumvi published in JAMA Neurology
- TG Therapeutics price target lowered to $46 from $49 at JPMorgan